Ratio Therapeutics to Establish New Radiopharmaceutical Manufacturing Facility
New facility will be part of Wasatch Group's Medical Innovation Technology Research Campus, a premier hub for cutting-edge medical manufacturing and collaboration located in Salt Lake City, Utah
BOSTON, May 8, 2025 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced that it entered into an agreement with the Medical Innovation Technology Management division of Wasatch Group to partner and construct a state-of-the-art radiopharmaceutical research and manufacturing facility in Salt Lake City, Utah, anticipated to be fully operational in the second half of 2027.
This 65,000 square foot manufacturing facility will support vertical integration of Ratio's current and future pipeline of next-generation radiopharmaceuticals, with the capacity to efficiently scale manufacturing for future commercial needs as Ratio advances its candidates through clinical trials. The facility will enable end-to-end production capabilities while allowing the company to leverage the region's robust radiopharmaceutical supply network and proximity to an international airport with central North American access, positioning Ratio to meet the complex supply chain demands of radiopharmaceutical development and commercialization.
"Ratio is excited to partner with Wasatch, who is ambitiously driving our field forward. With our pipeline advancing rapidly, securing a strategic manufacturing footprint is crucial to our long-term vision," said Jack Hoppin, Ph.D., Chairman and Chief Executive Officer of Ratio. "This facility not only places us near potential suppliers, such as Nusano, but also provides the infrastructure needed to meet future manufacturing demands at commercial scale and represents a major step toward Ratio's mission of developing and rapidly transitioning innovative radiopharmaceuticals to the clinic."
"We are thrilled to welcome Ratio Therapeutics as the first tenant in our Medical Innovation Technology Research and Development Park, which we designed specifically to foster the medical breakthroughs of tomorrow," said Tanner J.M. Bowman, President of MIT Management. "Ratio's cutting-edge work in radiopharmaceuticals perfectly aligns with our vision for this innovation hub. At Wasatch, we take a value-driven approach to business while never losing sight of what matters most: the people whose lives will be improved through these medical advancements. This partnership not only brings high-quality jobs to Salt Lake Valley but also strengthens Utah's growing reputation as a center for healthcare innovation. We're proud to provide the environment that will help Ratio deliver life-changing cancer treatments to patients in need."
About Wasatch Group
For over 33 years, the Wasatch Group has built businesses that span commercial and multi-family residential real estate development and management, medical technology, property innovation, consumer products manufacturing and venture capital. Wasatch has created growth and opportunities in its business through intelligent investments and philanthropic initiatives that are ingrained in its business model. Wasatch helps communities thrive through creative collaboration, responsible stewardship and fostering growth.
About the MIT Campus
The Medical Innovation Technology Campus is home to a range of startup companies, medical labs, and research facilities. With four complexes, comprised of multiple buildings, this campus aims to drive collaboration within the Salt Lake Valley in proximity to The University of Utah and other healthcare giants.
Just 15 minutes from the Salt Lake International Airport, 10 minutes from Downtown Salt Lake City, and access to various arterials to Salt Lake and Utah counties, the Medical Innovation Technology Campus is a hub for companies seeking a central location in Western United States.
https://www.wasatchgroup.com/divisions/mitm
About Ratio Therapeutics
Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. The company is also currently advancing the development of its first FAP-targeted radiotherapeutic with plans to enter clinical trials this year.
Please visit www.ratiotx.com for more information and follow us on Twitter (X) and LinkedIn.
SOURCE Ratio Therapeutics Inc.
Share this article